Opendata, web and dolomites

THERADNET SIGNED

International NETwork for training and innovations in THErapeutic RADiation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THERADNET project word cloud

Explore the words cloud of the THERADNET project. It provides you a very rough idea of what is the project "THERADNET" about.

metabolism    innovation    treatment    radiotherapy    microenvironment    situation    countries    co    immune    50    close    personalized    tumor    metastatic    irradiated    academia    substantial    students    radiation    regrowth    hypotheses    resistance    cancer    outcome    patients    biological    guarantee    adverse    care    alone    employability    dampen    60    science    optimized    performed    training    precision    cooperate    despite    outstanding    radiobiological    combatting    outgrowth    pursuit    expertise    clinical    disease    window    primary    multimodality    medicine    network    successful    community    small    widen    plasticity    innovations    intrinsic    acquired    prior    integrating    cured    biologically    health    critical    death    modalities    understand    stimulate    innovative    radiobiology    integration    premises    altered    mass    normal    therapy    approximately    translational    therapeutic    dose    recurrence    tissues    improvements    surrounding    standard    45    individual    sectors    collaborations    limiting    international    models    benefit    industry    reactions    combined   

Project "THERADNET" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT ZURICH 

Organization address
address: RAMISTRASSE 71
city: ZURICH
postcode: 8006
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 4˙026˙324 €
 EC max contribution 4˙026˙324 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2023-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT ZURICH CH (ZURICH) coordinator 562˙553.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 606˙345.00
3    INSTITUT CURIE FR (PARIS) participant 549˙604.00
4    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 531˙239.00
5    UNIVERSITE CATHOLIQUE DE LOUVAIN BE (LOUVAIN LA NEUVE) participant 512˙640.00
6    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 505˙576.00
7    UNIVERSITAETSKLINIKUM ESSEN DE (ESSEN) participant 505˙576.00
8    WESTDEUTSCHES PROTONENTHERAPIEZENTRUM ESSEN (WPE) GGMBH DE (ESSEN) participant 252˙788.00

Map

 Project objective

Radiotherapy alone or in multimodality approaches is applied in 45-60% of all cancer patients, but despite technical innovations approximately only 50% are cured. Disease recurrence may be due to regrowth of the primary tumor or metastatic outgrowth. Intrinsic and acquired resistance of the tumor and adverse reactions in the co-irradiated surrounding normal tissues dampen a successful therapy outcome. Substantial improvements are now expected from biologically optimized, personalized radiotherapy. This network is built on the premises that integration of novel-emerging radiobiological and tumor-biological concepts into current standard-of-care will improve outcome of radiotherapy-treated cancer patients. As the field of radiobiology is small in individual countries, it is essential to cooperate on the European level to achieve a critical mass for innovation in research and training. The partners in this network will stimulate outstanding science to understand the plasticity of an altered tumor metabolism and tumor microenvironment, including the immune system, prior to, and in response to radiotherapy, as well as related dose-limiting adverse effects in normal tissues. Research and development of novel combined treatment modalities in these areas will be performed in models as close as possible to the clinical situation to evaluate their potential to widen the therapeutic window beyond standard-of-care. Students will benefit from outstanding expertise and collaborations within academia and industry integrating novel concepts into translational cancer and radiation research. This will guarantee high employability in various sectors of cancer research and precision medicine. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combatting a major death-related disease in Europe, this project will raise health and bring long-term benefit to the European and international community.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERADNET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERADNET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ARCH (2019)

AGE-RELATED CHANGES IN HEMATOPOIESIS

Read More  

DELIVER (2019)

DELIVERy of advanced therapies for diabetes training network

Read More  

CHANGE (2019)

Cultural Heritage Analysis for New GEnerations

Read More